Ads
related to: novartis- Contact Us
Contact a PYLARIFY sales
representative to stay updated.
- Resources for PYLARIFY
Discover downloadable guides for
health care professionals.
- PYLARIFY Imaging Sites
Find or register a PYLARIFY
imaging site.
- PYLARIFY Case Studies
Review actual case study
findings for PYLARIFY.
- Contact Us
Search results
Pharmaceutical Giant Cencora Confirms Patient Data Breach Impacting over a Dozen Pharma Companies -...
CPO Magazine· 4 days agoU.S. pharmaceutical giant Cencora has disclosed that the February 2024 data breach leaked sensitive...
Novartis leukemia drug more effective than older treatments in trial
Reuters via Yahoo News· 3 days agoSwiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a...
Lawsuits pile up over state laws on discounts for hospitals' contract pharmacies
Reuters· 2 hours agoThe pharmaceutical industry has filed at least four lawsuits this year challenging state laws...
SageView Advisory Group LLC Acquires 718 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 7 days agoSageView Advisory Group LLC boosted its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 30.6% in the fourth quarter, according to the company in its most recent ...
Novartis study points to larger role for targeted leukemia drug
BioPharma Dive via Yahoo Finance· 4 days agoThe results are from a late-stage clinical trial run by Scemblix’s maker, Novartis, and will be...
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Zacks· 4 days agoNovartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Novartis Sues to Block Maryland's New Drug Discount Law - Novartis (NYSE:NVS)
Benzinga· 3 days agoNovartis AG NVS has reportedly filed a lawsuit to block a Maryland law requiring drugmakers to offer...
Novartis sues Maryland over law prohibiting restrictions on 340B drugs
Becker’s Hospital Review· 4 days ago"Novartis sues Maryland over new law restricting 340B drug pricing program, citing conflict with federal law and potential harm to constitutional rights."
Novartis reports Phase III data for trials of remibrutinib to treat CSU
Clinical Trials Arena via Yahoo Finance· 4 days agoNovartis has released new data from two Phase III clinical trials confirming the sustained efficacy...
Novartis stock rated 'Buy' by Goldman Sachs, highlighting robust innovation By Investing.com
Investing.com· 5 days agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on Novartis AG (SIX:NOVN) stock, listed as...